Medicine Matters diabetes

The 15-year results of the VADT reveal that the legacy cardioprotective effect of intensive glycemic control seen at the 10-year follow-up has now disappeared.

Researchers speaking at the ADA’s 78th Scientific Sessions in Orlando, Florida, USA, have presented data from The Environmental Determinants of Diabetes in the Young study that begin to shed light on genetic and environmental triggers of pediatric type 1 diabetes.

Many parents underestimate their child’s risk for type 1 diabetes, and although accuracy improves following a positive autoantibody result, it subsequently declines with time, a survey of TEDDY participants shows.

Fully closed-loop insulin delivery results in a markedly improved time in range among inpatients with type 2 diabetes receiving noncritical care, researchers have reported.

The RISE trial investigators have found that increased insulin resistance and hyperresponsive beta cells may explain the rapid progression of type 2 diabetes in children.

MEDI0382, a novel glucagon-like peptide-1 and glucagon receptor dual agonist, induces clinically meaningful improvements in glycemic control and bodyweight in patients with type 2 diabetes, show data published in The Lancet.

A pilot study suggests that patients may be more diligent attenders of the US National Diabetes Prevention Program if they first attend a pre-course session focused on the program’s goals and barriers to its attendance.

Patients with type 1 diabetes who move to a DIY closed-loop insulin delivery system have significant improvements in their glycemic control, shows an analysis of continuous glucose monitoring data.

South Asian women who assimilate American culture following migration to the USA have a more favorable cardiometabolic risk profile than those who maintain a preference for South Asian culture, results of the MASALA study show.

Patients using the MiniMed 670G hybrid closed-loop system in the real world achieve similar glycemic control to patients who used it in the pivotal clinical trial, researchers have reported.

The DEPICT-2 findings confirm those of DEPICT-1, with dapagliflozin producing improved glycemic control and weight loss, and reduced insulin need, in patients with type 1 diabetes.

The DEPICT-1 and inTandem1 investigators have released their 52-week findings, revealing persistent reductions in glycated hemoglobin with SGLT2 inhibition, but a slightly increased risk for diabetic ketoacidosis.

Insulin titration benefits individuals with type 2 diabetes regardless of age or whether it is self- or physician-managed, according to data presented at the ADA’s 78th Scientific Sessions in Orlando, Florida, USA.

Insulin glargine-300 and insulin degludec-100 provide a similar level of glycemic control in patients with poorly controlled type 2 diabetes, results of the BRIGHT study show.

Dapagliflozin plus saxagliptin offers a realistic alternative to both insulin and glimepiride in patients with type 2 diabetes poorly controlled by metformin, show two studies presented at the ADA’s 78th Scientific Sessions in Orlando, Florida, USA.

Changes in the gut microbiome, microRNAs, glucose response curves, and pancreas volume may all be associated with progression to type 1 diabetes, reported researchers at the ADA’s 78th Scientific Sessions in Orlando, Florida, USA.

Analysis of the Health and Retirement Study indicates that the adverse effects of earlier age of type 2 diabetes onset are also evident in an older population.

Degludec delivers the same magnitude of protection against hypoglycemia relative to glargine across patient age groups, shows analysis of the SWITCH 2 and DEVOTE trials.

Only a very small proportion of adolescents and young adults with diabetes who are referred for outpatient psychotherapy actually receive these services, even when there is an integrated pediatric psychologist in the clinic, research shows.

The ASK study findings show that around 1% of children in the general population are at high risk for diabetes, and the majority of these have no family history of the condition.

A pharmacist-led shared decision-making intervention significantly increases the uptake of lifestyle-change programs and metformin use in patients with prediabetes, results of the PRIDE study show.

Gastric bypass surgery benefits obese patients with type 2 diabetes in many ways, but such benefits come at a cost, show data presented at the ADA’s 78th Scientific Sessions in Orlando, Florida.

Patients who experience hypoglycemia during intensive insulin therapy after coronary artery bypass graft surgery may be at increased risk for dying during the next year, suggests research presented at the ADA’s 78th Scientific Sessions.

Researchers have reported that around one in 10 patients with insulin-dependent type 2 diabetes have impaired hypoglycemia awareness.